United Capital Financial Advisors LLC Has $1.33 Million Position in Cencora, Inc. (NYSE:COR)

United Capital Financial Advisors LLC lowered its position in Cencora, Inc. (NYSE:COR - Free Report) by 26.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,900 shares of the company's stock after selling 2,153 shares during the quarter. United Capital Financial Advisors LLC's holdings in Cencora were worth $1,326,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of COR. Hickory Asset Management Inc. acquired a new position in shares of Cencora in the 4th quarter worth approximately $572,000. Sylvest Advisors LLC acquired a new stake in shares of Cencora in the 4th quarter valued at $1,105,000. Insight Wealth Strategies LLC boosted its stake in shares of Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after purchasing an additional 11,232 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after purchasing an additional 1,995 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Cencora by 71.1% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock worth $1,583,000 after purchasing an additional 2,928 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Trading Down 0.5 %

Shares of Cencora stock traded down $1.48 on Thursday, hitting $283.23. 472,386 shares of the company's stock traded hands, compared to its average volume of 1,508,687. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock has a market capitalization of $54.92 billion, a PE ratio of 40.27, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The firm's 50-day moving average price is $266.42 and its two-hundred day moving average price is $248.28.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.78%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Analyst Ratings Changes

COR has been the topic of several research analyst reports. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Wells Fargo & Company increased their target price on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $284.55.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the transaction, the chairman now directly owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,223 shares of company stock worth $13,580,967. Company insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.